NACDS backs e-prescribing Senate bill
The National Association of Chain Drug Stores is backing legislation introduced in the Senate that would require electronic prescribing of controlled substances for Medicare Part D beneficiaries. The Every Prescription Conveyed Securely Act was introduced Tuesday by Sens. Michael Bennet, D-Colo., and Dean Heller, R-Nev., with Sens. Elizabeth Warren, D-Mass., and Pat Toomey, R-Pa., as co-sponsors.
“NACDS appreciates the leadership of Senators Bennet, Helller, Warren and Toomey in this important work to help confront the opioid-abuse epidemic,” NACDS President and CEO Steve Anderson said. “Electronic prescribing enhances security and curbs waste, fraud and abuse. This legislation is a vital aspect of a more comprehensive and effective approach to protecting families and communities.”
NACDS was one of ten associations and companies to send the senators a letter showing their support for the legislation. In the letter, the Arlington, Va.-based trade organization outlines the advantages of e-prescribing controlled substances, including the ease with which these prescriptions can be tracked and their resistance to forgery. E-prescribing of controlled substances has been a policy goal of NACDS’ and was included in its October letter that outlined its various policy stances to the President’s Commission on Combating Drug Addiction and the Opioid Crisis. NACDS said that its advocated policies are based on based on pharmacists’ experience on the front lines of healthcare, and are based on pharmacy’s longstanding collaboration with law enforcement and health professionals on the complex issue of opioid-abuse prevention.
In January, a Morning Consult poll commissioned by NACDS found that 76% of voters support a requirement to handle all prescriptions electronically as a way to combat the opioid epidemic.
Dr. Reddy’s intros generic Xenazine
Dr. Reddy’s recently launched its generic Xenazine (tetrabenazine tablets). The product is indicated to treat chorea, or involuntary movements, of Huntington’s Disease.
Dr. Reddy’s generic Xenazine will be available in 12.5- and 25-mg dosage strengths. The product had a U.S. market size of roughly $322 million for the 12 months ended November 2017, according to IQVIA data.
The drug contains a boxed warning about its potential to increase the risk of depression and suicidality in patients.
Mayne Pharma launches generic Ritalin LA in new strength
Mayne Pharma is introducing its generic Ritalin LA (methylphenidate extended-release) capsules in 10-mg dosage strength — the first available in this strength. The product is indicated to treat attention deficit hyperactivity disorder.
“This launch reinforces Mayne Pharma’s commitment to expanding its on-market portfolio,” Mayne Pharma CEO Scott Richards said. “This will be the first generic alternative of the 10-mg dose strength, providing more choices to patients in terms of medication affordability. Mayne Pharma directly markets more than 55 products, and has a growing pipeline of more than 35 generic drug products targeting U.S. markets with [IQVIA] sales greater than $5 billion.”
The generic Ritalin LA 10-mg capsules will join the companies preexisting line of 20-, 30-, 40- and 60-mg dosage strengths of the product. Brand sales of Ritalin LA were roughly $21 million for the 12 months ended December 31, 2017, according to IQVIA data.